



PRIOR AUTHORIZATION POLICY

POLICY: Inflammatory Conditions – Tocilizumab Subcutaneous Products Prior Authorization Policy

- Actemra® (tocilizumab subcutaneous injection – Genentech/Roche)
- Avtozma® (tocilizumab-anoh subcutaneous injection – Celltrion)
- Tyenne® (tocilizumab-aazg subcutaneous injection – Fresenius Kabi)

REVIEW DATE: 04/29/2026

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Tocilizumab subcutaneous injection, an interleukin-6 (IL-6) receptor inhibitor, is indicated for the following uses:¹

- **Giant cell arteritis** in adults.
- **Interstitial lung disease associated with systemic sclerosis**, to slow the rate of decline in pulmonary function in adults.
- **Polyarticular juvenile idiopathic arthritis**, for the treatment of active disease in patients ≥ 2 years of age.
- **Rheumatoid arthritis**, for treatment of adults with moderate to severe active disease who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

- **Systemic juvenile idiopathic arthritis**, for the treatment of active disease in patients ≥ 2 years of age.

Guidelines/Clinical Efficacy

IL-6 blockers are mentioned in multiple guidelines for treatment of inflammatory conditions. Clinical data also support use of tocilizumab in other conditions.

- **Giant Cell Arteritis:** Recommendations from the European League Against Rheumatism (EULAR) [2023] state the diagnosis of giant cell arteritis may be made without biopsy if there is a high suspicion of giant cell arteritis and a positive imaging test.² The ACR/Vasculitis Foundation (2021) conditionally recommend for newly diagnosed giant cell arteritis initiating treatment tocilizumab and oral glucocorticoids over oral glucocorticoids alone.¹³ For patients who experience disease relapse with symptoms of cranial ischemia while receiving glucocorticoids, they conditionally recommend adding tocilizumab and increasing the dose of glucocorticoids over adding methotrexate and increasing the dose of glucocorticoids. In the pivotal trial evaluating tocilizumab subcutaneous for giant cell arteritis (n = 251), patients were treated with corticosteroids in an open-label fashion (20 mg to 60 mg/day) during the screening period prior to treatment with tocilizumab subcutaneous.^{3,4} Sustained remission at Week 52 was achieved in 56% of patients who received tocilizumab subcutaneous every week + 26-week prednisone taper and 53% of patients who received tocilizumab every other week + 26-week prednisone taper vs. 14% of patients in the 26-week prednisone taper and 18% of patients in the 52-week prednisone taper.
- **Interstitial Lung Disease Associated with Systemic Sclerosis (SSc-ILD):** EULAR guidelines for systemic sclerosis (2023) address tocilizumab.⁵ Regarding patients with lung involvement, tocilizumab may be considered for treatment of SSc-ILD (level of evidence: 1b; strength of recommendation: A). In the pivotal trial evaluating tocilizumab subcutaneous for systemic sclerosis-associated interstitial lung disease, patients were required to have a percentage of predicted forced vital capacity (FVC% predicted) $> 55\%$.⁶ Among patients with interstitial lung disease confirmed on high-resolution computed tomography scan (n = 136), the change from baseline in FVC% predicted at Week 48 was significantly improved in the group taking tocilizumab (0.07 vs. -6.40 with placebo).
- **Polyarticular Juvenile Idiopathic Arthritis:** The American College of Rheumatology (ACR)/Arthritis Foundation guidelines for the treatment of Juvenile Idiopathic Arthritis (2019) are specific to juvenile non-systemic polyarthritis, sacroiliitis, and enthesitis.⁷ For patients without risk factors, initial therapy with a DMARD is conditionally recommended over a biologic (including tocilizumab). Biologics (e.g., tocilizumab) are conditionally recommended as initial treatment when combined with a DMARD over biologic monotherapy.
- **Polymyalgia Rheumatica:** Guidelines from the European League Against Rheumatism (EULAR)/ACR (2015) mention case reports with tocilizumab and an ongoing study.⁸ The minimum effective individualized duration of glucocorticoid therapy is strongly recommended.

- **Rheumatoid Arthritis:** Guidelines from the ACR for the treatment of rheumatoid arthritis (2021) have tumor necrosis factor (TNF) inhibitors and non-TNF biologics (such as tocilizumab) equally positioned as a recommended therapy following a trial of a conventional synthetic DMARD (e.g., methotrexate, leflunomide, hydroxychloroquine, sulfasalazine).⁹
- **Still's Disease (Systemic Juvenile Idiopathic Arthritis [sJIA] and Adult Onset Still's Disease [AOSD]):** The European Alliance of Associations for Rheumatology (EULAR) and Pediatric Rheumatology European Society (PReS) joint clinical guidelines for management of Still's disease (2024) recognize sJIA and AOSD as the same disease, differing only in age of onset. Therefore, they can collectively be referred to as Still's disease.¹⁰ Guidelines recommend an IL-1 or an IL-6 inhibitor be initiated as early as possible when the diagnosis is established.
- **Vacuoles E1 Enzyme X-linked Autoinflammatory Somatic (VEXAS) Syndrome:** VEXAS is an adult-onset autoinflammatory condition caused by somatic mutations in the *UBA1* gene, which disrupts the function of the E1 enzyme responsible for protein cleanup inside cells. This leads to a buildup of damaged proteins, triggering widespread inflammation. It presents with a combination of systemic inflammation and hematologic abnormalities. The American College of Rheumatology (ACR) [2025] provides a guidance statement for the diagnosis and management of VEXAS syndrome.¹² Regarding diagnosis, ACR notes that the majority of patients with typical VEXAS have missense or splice site mutations at exon 3 of *UBA1*. For patients that are negative with genetic testing for mutations in *UBA1*, clinicians should ensure that testing covers the complete gene and consider testing a bone marrow sample. For treatment of inflammatory manifestations, corticosteroids are recommended. ACR lists tocilizumab IV or SC as a potential treatment option for relapse or as a corticosteroid-sparing agent.

POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of tocilizumab subcutaneous. All approvals are provided for the approval duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of a patient treated with tocilizumab subcutaneous as well as the monitoring required for adverse events and long-term efficacy, initial approval requires tocilizumab subcutaneous to be prescribed by or in consultation with a physician who specializes in the condition being treated.

- **Actemra (tocilizumab subcutaneous injection - Genentech/Roche)**
- **Avtozma® (tocilizumab-anoh subcutaneous injection - Celltrion)**
- **Tyenne® (tocilizumab-aazg subcutaneous injection - Fresenius Kabi)**

is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):

FDA-Approved Indications

1. Giant Cell Arteritis. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):

- i.** Patient is ≥ 18 years of age; AND
- ii.** Patient has tried or is currently taking a systemic corticosteroid, or systemic corticosteroids are contraindicated; AND

Note: An example of a systemic corticosteroid is prednisone.

- iii.** The medication is prescribed by or in consultation with a rheumatologist; OR

B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i.** Patient has been established on the requested medication for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).

- ii.** Patient meets at least ONE of the following (a or b):

- a)** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating a tocilizumab product); OR

Note: Examples of objective measures are serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), resolution of fever, and/or reduced dosage of corticosteroids.

- b)** Compared with baseline (prior to initiating a tocilizumab product), patient experienced an improvement in at least one symptom, such as decreased headache, scalp or jaw pain, decreased fatigue, and/or improved vision.

2. Interstitial Lung Disease Associated with Systemic Sclerosis. Approve for 1 year if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve if the patient meets ALL of the following (i, ii, iii, iv, and v):

- i.** Patient is ≥ 18 years of age; AND

- ii.** Patient has elevated acute phase reactants, defined as at least ONE of the following (a, b, or c):

- a)** C-reactive protein (CRP) ≥ 6 mg/mL; OR

- b)** Erythrocyte sedimentation rate (ESR) ≥ 28 mm/h; OR

- c)** Platelet count $\geq 330 \times 10^9/L$; AND

- iii.** Forced vital capacity (FVC) is $> 55\%$ of the predicted value; AND

- iv.** Diagnosis is confirmed by high-resolution computed tomography; AND

- v.** The medication is prescribed by or in consultation with a pulmonologist or a rheumatologist; OR

B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product. Approve if the patient meets ALL of the following (i, ii, and iii):

- i.** Patient is ≥ 18 years of age; AND

- ii. Patient has experienced a beneficial response to therapy over the previous 1 year while receiving a tocilizumab product; AND
Note: For a patient who has received less than 1 year of therapy, response to therapy is from baseline prior to initiating a tocilizumab product. Examples of a beneficial response include a reduction in the anticipated decline in forced vital capacity, improvement in 6-minute walk distance, and/or reduction in the number or severity of disease-related exacerbations.
- iii. The medication is prescribed by or in consultation with a pulmonologist or a rheumatologist.

3. Polyarticular Juvenile Idiopathic Arthritis. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):

- i. Patient is ≥ 2 years of age; AND
- ii. Patient meets ONE of the following (a, b, c, or d):
 - a) Patient has tried one other systemic therapy for this condition; OR
Note: Examples of other systemic therapies include methotrexate, sulfasalazine, leflunomide, or a nonsteroidal anti-inflammatory drug (NSAID). A previous trial of one biologic other than the requested drug also counts as a trial of one systemic therapy for Juvenile Idiopathic Arthritis. A biosimilar of Actemra does not count. Refer to [Appendix](#) for examples of biologics used for Juvenile Idiopathic Arthritis.
 - b) Patient will be starting on tocilizumab subcutaneous concurrently with methotrexate, sulfasalazine, or leflunomide; OR
 - c) Patient has an absolute contraindication to methotrexate, sulfasalazine, or leflunomide; OR
Note: Examples of absolute contraindications to methotrexate include pregnancy, breastfeeding, alcoholic liver disease, immunodeficiency syndrome, and blood dyscrasias; OR
 - d) Patient has aggressive disease, as determined by the prescriber; AND
- iii. The medication is prescribed by or in consultation with a rheumatologist; OR

B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on the requested medication for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).
- ii. Patient meets at least ONE of the following (a or b):
 - a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating a tocilizumab product); OR
Note: Examples of objective measures include Physician Global Assessment (MD global), Parent/Patient Global Assessment of Overall

Well-Being (PGA), Parent/Patient Global Assessment of Disease Activity (PDA), Juvenile Arthritis Disease Activity Score (JDAS), Clinical Juvenile Arthritis Disease Activity Score (cJDAS), Juvenile Spondyloarthritis Disease Activity Index (JSpADA), serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.

- b)** Compared with baseline (prior to initiating a tocilizumab product), patient experienced an improvement in at least one symptom, such as improvement in limitation of motion, less joint pain or tenderness, decreased duration of morning stiffness or fatigue, improved function or activities of daily living.

4. Rheumatoid Arthritis. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii and iii):

- i.** Patient is ≥ 18 years of age; AND
- ii.** Patient has tried one conventional synthetic disease-modifying antirheumatic drug (DMARD) for at least 3 months; AND

Note: Examples of conventional DMARDs include methotrexate (oral or injectable), leflunomide, hydroxychloroquine, and sulfasalazine. An exception to the requirement for a trial of one conventional synthetic DMARD can be made if the patient has already had a 3-month trial with at least one biologic other than a tocilizumab product. A biosimilar of Actemra does not count. Refer to [Appendix](#) for examples of biologics used for rheumatoid arthritis. A patient who has already tried a biologic for rheumatoid arthritis is not required to “step back” and try a conventional synthetic DMARD.

- iii.** The medication is prescribed by or in consultation with a rheumatologist; OR

B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i.** Patient has been established on the requested medication for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).

- ii.** Patient meets at least ONE of the following (a or b):

- a)** Patient experienced a beneficial clinical response when assessed by at least one objective measure; OR

Note: Examples of standardized and validated measures of disease activity include Clinical Disease Activity Index (CDAI), Disease Activity Score (DAS) 28 using erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP), Patient Activity Scale (PAS)-II, Rapid Assessment of Patient Index Data 3 (RAPID-3), and/or Simplified Disease Activity Index (SDAI).

- b)** Patient experienced an improvement in at least one symptom, such as decreased joint pain, morning stiffness, or fatigue; improved function or

activities of daily living; decreased soft tissue swelling in joints or tendon sheaths.

5. Systemic Juvenile Idiopathic Arthritis. Approve for the duration noted if the patient meets ONE of the following (A or B):

Note: Systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD) are considered the same disease (Still's disease) but differ in age of onset. For a patient ≥ 18 years of age, refer to AOSD indication below.

A) Initial Therapy. Approve for 6 months if the patient meets BOTH of the following (i and ii):

- i. Patient is ≥ 2 years of age; AND
- ii. The medication is prescribed by or in consultation with a rheumatologist;
OR

B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i. Patient has been established on the requested medication for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).

- ii. Patient meets at least ONE of the following (a or b):

- a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR

Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.

- b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as less joint pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living.

Other Uses with Supportive Evidence

6. Polymyalgia Rheumatica. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, and iii):

- i. Patient is ≥ 18 years of age; AND
- ii. Patient has tried one systemic corticosteroid; AND

Note: An example of a systemic corticosteroid is prednisone.

- iii. The medication is prescribed by or in consultation with a rheumatologist;
OR

B) Patient is Currently Receiving a Tocilizumab Subcutaneous or Intravenous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

i. Patient has been established on the requested medication for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).

ii. Patient meets at least ONE of the following (a or b):

a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating a tocilizumab product); OR

Note: Examples of objective measures are serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), resolution of fever, and/or reduced dosage of corticosteroids.

b) Compared with baseline (prior to initiating a tocilizumab product), patient experienced an improvement in at least one symptom, such as decreased shoulder, neck, upper arm, hip, or thigh pain or stiffness; improved range of motion; and/or decreased fatigue.

7. Still's Disease, Adult Onset. Approve for the duration noted if the patient meets the following criteria (A or B):

Note: Adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are considered the same disease (Still's disease) but differ in age of onset. For a patient < 18 years of age, refer to the SJIA indication above.

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i and ii):

i. Patient is \geq 18 years of age; AND

ii. The medication is prescribed by or in consultation with a rheumatologist;
OR

B) Patient is Currently Receiving a Tocilizumab Intravenous or Subcutaneous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

i. Patient has been established on the requested medication for at least 6 months; AND

Note: A patient who has received < 6 months of therapy or who is restarting therapy with this medication is reviewed under criterion A (Initial Therapy).

ii. Patient meets at least ONE of the following (a or b):

a) When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR

Note: Examples of objective measures include resolution of fever, improvement in rash or skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.

b) Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as less joint

pain/tenderness, stiffness, or swelling; decreased fatigue; improved function or activities of daily living.

8. Vacuoles E1 Enzyme X-linked Autoinflammatory Somatic (VEXAS) Syndrome. Approve for the duration noted if the patient meets ONE of the following (A or B):

A) Initial Therapy. Approve for 6 months if the patient meets ALL of the following (i, ii, iii, and iv):

- i.** Patient is ≥ 18 years of age; AND
- ii.** Patient has a molecular genetic test demonstrating pathogenic or likely pathogenic *UBA1* gene variant; AND
- iii.** Patient meets ONE of the following (a or b):
 - a)** Patient has tried or is currently taking a systemic corticosteroid; OR
 - b)** Systemic corticosteroids are contraindicated; AND
- iv.** The medication is prescribed by or in consultation with a rheumatologist, hematologist, dermatologist, immunologist, or specialist in the treatment of autoinflammatory conditions; OR

B) Patient is Currently Receiving a Tocilizumab Intravenous or Subcutaneous Product. Approve for 1 year if the patient meets BOTH of the following (i and ii):

- i.** Patient has been established on the requested medication for at least 6 months; AND
Note: A patient who has received < 6 months of therapy or who is restarting therapy is reviewed under criterion A (Initial Therapy).
- ii.** Patient meets at least ONE of the following (a or b):
 - a)** When assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline (prior to initiating the requested drug); OR
Note: Examples of objective measures include resolution of fever, improvement in skin manifestations, clinically significant improvement or normalization of serum markers (e.g., C-reactive protein, erythrocyte sedimentation rate), and/or reduced dosage of corticosteroids.
 - b)** Compared with baseline (prior to initiating the requested drug), patient experienced an improvement in at least one symptom, such as decreased joint pain, decreased fatigue, decreased cough and/or dyspnea, improved ocular symptoms, and/or improved function or activities of daily living.

CONDITIONS NOT COVERED

- Actemra (tocilizumab subcutaneous injection - Genentech/Roche)
- Avtozma® (tocilizumab-anoh subcutaneous injection - Celltrion)
- Tyenne® (tocilizumab-aazg subcutaneous injection - Fresenius Kabi)

is(are) considered not medically necessary for ANY other use(s) including the following (this list may not be all inclusive; criteria will be updated as new published data are available):

1. Concurrent Use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug. This medication should not be administered in combination with another biologic or with a targeted synthetic oral small molecule drug used for an inflammatory condition (see [Appendix](#) for examples). Combination therapy is generally not recommended due to a potentially higher rate of adverse events and lack of controlled clinical data supporting additive efficacy.

Note: This does NOT exclude the use of conventional synthetic DMARDs (e.g., methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) in combination with this medication.

2. Crohn's Disease. In a 12-week pilot study conducted in Japan, 36 adults with active Crohn's disease (Crohn's Disease Activity Index [CDAI] \geq 150 and increased C-reactive protein [CRP]) were randomized in a double-blind fashion to intravenous tocilizumab 8 mg/kg every 2 weeks, or alternating infusions of tocilizumab 8 mg/kg every 4 weeks and placebo (i.e., alternating with placebo every 2 weeks), or to placebo every 2 weeks.¹¹ At baseline, the mean CDAI ranged from 287 to 306. Patients had been treated with corticosteroids, mesalamine-type drugs, metronidazole, or elemental diet. Six patients in the placebo group, four on tocilizumab every 4 weeks, and one on tocilizumab every 2 weeks dropped out. The mean reduction in the CDAI score in the tocilizumab 8 mg/kg every 2 week group was 88 points – from (mean) 306 to 218. Further studies are needed.

REFERENCES

1. Actemra® [prescribing information]. South San Francisco, CA: Genentech; December 2025.
2. Dejaco C, Ramiro S, Bond M, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. *Ann Rheum Dis.* 2024;83:741-751.
3. Tuckwell K, Collinson N, Dimonaco S, et al. Newly diagnosed vs. relapsing giant cell arteritis: baseline data from the GiACTA trial. *Semin Arthritis Rheum.* 2017;46(5):657-664.
4. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. *N Engl J Med.* 2017 ;377(4):317-328
5. Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. *Ann Rheum Dis.* 2025 Jan;84(1):29-40. doi: 10.1136/ard-2024-226430. [Epub].
6. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respir Med.* 2020;8(10):963-974.
7. Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. *Arthritis Care Res.* 2019;71(6):717-734.
8. Dejaco C, Singh YP, Perel P, et al. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. *Ann Rheum Dis.* 2015;74(10):1799-807.
9. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol.* 2021;73(7):1108-1123.
10. Fautrel B, Mitrovic S, De Matteis A, et al. EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease. *Ann Rheum Dis.* 2024;83(12):1614-1627.
11. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. *Gastroenterology.* 2004;126:989-996.
12. Mekinian AM, Georgin-Lavaille S, Ferrada MA, et al. American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working

Group Expert Panel. *Arthritis Rheumatol.* 2025 Aug 11. doi: 10.1002/art.43287 [Online ahead of print].

13. Maz M, Chung SA, Abril A et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. *Arthritis Rheumatol.* 2021 Aug;73(8):1349-1365.

HISTORY

Type of Revision	Summary of Changes	Review Date
Early Annual Revision	Policy was renamed as Inflammatory Conditions – Tocilizumab Subcutaneous Products. Throughout the policy, wording was changed from Actemra to tocilizumab. Systemic Juvenile Idiopathic Arthritis: The Note was revised to remove tumor necrosis factor inhibitors from the examples of other systemic therapies that could have been tried prior to Actemra subcutaneous.	04/24/2024
Selected Revision	Tyenne subcutaneous was added to the policy with the same criteria as the other Actemra subcutaneous products.	06/26/2024
Selected Revision	Giant Cell Arteritis: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Polyarticular Juvenile Idiopathic Arthritis: For initial approvals, a requirement that the patient is ≥ 2 years of age was added. Rheumatoid Arthritis: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Systemic Juvenile Idiopathic Arthritis: For initial approvals, a requirement that the patient is ≥ 2 years of age was added. Polymyalgia Rheumatica: For initial approvals, a requirement that the patient is ≥ 18 years of age was added. Conditions Not Covered : Concurrent use with a Biologic or with a Targeted Synthetic Oral Small Molecule Drug was changed to as listed (previously oral small molecule drug was listed as Disease-Modifying Antirheumatic Drug).	09/11/2024
Annual Revision	Removed the following from the Policy Statement: "All reviews for use of tocilizumab subcutaneous for Coronavirus Disease 2019 (COVID-19) and/or cytokine release syndrome associated with COVID-19 will be forwarded to the Medical Director." Conditions Not Covered : Removed COVID-19.	04/23/2025

HISTORY (CONTINUED)

Type of Revision	Summary of Changes	Review Date
Selected Revision	Giant Cell Arteritis: The requirement that the patient has tried one systemic corticosteroid was changed to now specify the patient has tried or currently is taking a systemic corticosteroid, unless a systemic corticosteroid is contraindicated. Systemic Juvenile Idiopathic Arthritis: The following Note was added "Systemic juvenile idiopathic arthritis (SJIA) and adult-onset Still's disease (AOSD) are considered the same disease (Still's disease) but differ in age of onset. For a patient ≥ 18 years of age, refer to AOSD indication." Additionally, the requirement for a previous trial of one other systemic therapy was removed. Still's Disease, Adult-Onset: The new condition of approval was added under other uses with supportive evidence.	06/11/2025
Selected Revision	Vacuoles E1 Enzyme X-linked Autoinflammatory Somatic (VEXAS) Syndrome: This new condition of approval was added under Other Uses with Supportive Evidence.	12/03/2025

	Appendix: Otezla XR (apremilast extended-release tablet) was added under the Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs.	
Selected Revision	Avtozma subcutaneous was added to the policy with the same criteria as the other tocilizumab subcutaneous products.	03/11/2026
Annual Revision	No criteria changes. Appendix: Icotyde (icotrokinra tablet) was added under Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs.	04/29/2026

APPENDIX

	Mechanism of Action	Examples of Indications*
Biologics		
Adalimumab SC Products (Humira®, biosimilars)	Inhibition of TNF	AS, CD, HS, JIA, PsO, PsA, RA, UC
Cimzia® (certolizumab pegol SC injection)	Inhibition of TNF	AS, CD, JIA, nr-axSpA, PsO, PsA, RA
Etanercept SC Products (Enbrel®, biosimilars)	Inhibition of TNF	AS, JIA, PsO, PsA, RA
Infliximab IV Products (Remicade®, biosimilars)	Inhibition of TNF	AS, CD, PsO, PsA, RA, UC
Zymfentra® (infliximab-dyyb SC injection)	Inhibition of TNF	CD, UC
Simponi®, Simponi Aria® (golimumab SC injection, golimumab IV infusion)	Inhibition of TNF	SC formulation: AS, PsA, RA, UC IV formulation: AS, PJIA, PsA, RA
Kineret® (anakinra SC injection)	Inhibition of IL-1	RA
Tocilizumab Products (Actemra® IV, biosimilars; Actemra SC, biosimilars)	Inhibition of IL-6	SC formulation: PJIA, RA, SJIA IV formulation: PJIA, RA, SJIA
Kezara® (sarilumab SC injection)	Inhibition of IL-6	PJIA, RA
Omvo® (mirikizumab IV infusion, SC injection)	Inhibition of IL-23	CD, UC
Ustekinumab Products (Stelara® IV, biosimilar; Stelara SC, biosimilar)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC
Siliq® (brodalumab SC injection)	Inhibition of IL-17	PsO
Cosentyx® (secukinumab SC injection; secukinumab IV infusion)	Inhibition of IL-17A	SC formulation: AS, ERA, HS, nr-axSpA, PsO, PsA IV formulation: AS, nr-axSpA, PsA
Taltz® (ixekizumab SC injection)	Inhibition of IL-17A	AS, nr-axSpA, PsO, PsA
Bimzelx® (bimekizumab-bkzx SC injection)	Inhibition of IL-17A/17F	AS, HS, nr-axSpA, PsO, PsA
Ustekinumab Products (Stelara® IV, biosimilars; Stelara SC, biosimilars)	Inhibition of IL-12/23	SC formulation: CD, PsO, PsA, UC IV formulation: CD, UC
Ilumya® (tildrakizumab-asmn SC injection)	Inhibition of IL-23	PsO
Skyrizi® (risankizumab-rzaa SC injection, risankizumab-rzaa IV infusion)	Inhibition of IL-23	SC formulation: CD, PSA, PsO, UC IV formulation: CD, UC
Tremfya® (guselkumab SC injection, guselkumab IV infusion)	Inhibition of IL-23	SC formulation: CD, PsA, PsO, UC IV formulation: CD, UC
Entyvio® (vedolizumab IV infusion, vedolizumab SC injection)	Integrin receptor antagonist	CD, UC
Orencia® (abatacept IV infusion, abatacept SC injection)	T-cell costimulation modulator	SC formulation: JIA, PSA, RA IV formulation: JIA, PsA, RA
Rituximab IV Products (Rituxan®, biosimilars)	CD20-directed cytolytic antibody	RA
Oral Therapies/Targeted Synthetic Oral Small Molecule Drugs		
Icotyde™ (icotrokinra tablets)	Inhibition of IL-23 receptor	PsO
Otezla® (apremilast tablets)	Inhibition of PDE4	PsO, PsA
Otezla XR™ (apremilast extended-release tablets)	Inhibition of PDE4	PsO, PsA
Sotyktu® (deucravacitinib tablets)	Inhibition of TYK2	PsO, PsA
Cibinqo™ (abrocitinib tablets)	Inhibition of JAK pathways	AD

Olumiant [®] (baricitinib tablets)	Inhibition of JAK pathways	RA, AA
Litfulo [®] (ritlecitinib capsules)	Inhibition of JAK pathways	AA
Legselvi [®] (deuruxolitinib tablets)	Inhibition of JAK pathways	AA
Rinvoq [®] (upadacitinib extended-release tablets)	Inhibition of JAK pathways	AD, AS, CD, nr-axSpA, PJIA, PsA, RA, UC
Rinvoq [®] LQ (upadacitinib oral solution)	Inhibition of JAK pathways	PJIA, PsA
Xeljanz [®] (tofacitinib tablets/oral solution)	Inhibition of JAK pathways	AS, PJIA, PsA, RA, UC
Xeljanz [®] (tofacitinib oral solution)	Inhibition of JAK pathways	PJIA, PsA
Xeljanz [®] XR (tofacitinib extended-release tablets)	Inhibition of JAK pathways	AS, PJIA, PsA, RA, UC
Zeposia [®] (ozanimod tablets)	S1PRM	UC
Velsipity [®] (etrasimod tablets)	S1PRM	UC

* Not an all-inclusive list of indications. Refer to the prescribing information for the respective agent for FDA-approved indications; SC – Subcutaneous; TNF – Tumor necrosis factor; AS – Ankylosing spondylitis; CD – Crohn’s disease; HS – Hidradenitis Suppurativa; JIA – Juvenile idiopathic arthritis; PsO – Plaque psoriasis; PsA – Psoriatic arthritis; RA – Rheumatoid arthritis; UC – Ulcerative colitis; nr-axSpA – Non-radiographic axial spondyloarthritis; IV – Intravenous, PJIA – Polyarticular juvenile idiopathic arthritis; IL – Interleukin; SJIA – Systemic juvenile idiopathic arthritis; ERA – Enthesitis-related arthritis; PDE4 – Phosphodiesterase 4; JAK – Janus kinase; AD – Atopic dermatitis; AA – Alopecia areata; TYK2 – Tyrosine kinase 2; S1PRM – Sphingosine 1-phosphate receptor modulator.

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2026 The Cigna Group.